UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer

BJU international, 2017-02, Vol.119 (2), p.239-244

2017

Volltextzugriff (PDF)

Indian Nationalism and the Early Congress

McLane, John R

1, 2015

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects

Therapeutic advances in urology, 2018-02, Vol.10 (2), p.43-50

2018

Volltextzugriff (PDF)

Analysis of common side effects of isotretinoin

Journal of the American Academy of Dermatology, 2001-11, Vol.45 (5), p.S188-S194

McLane, John

2001

Volltextzugriff (PDF)

MP73-16 SOLID DEPOT, CONTINUOUS RELEASE, SUBCUTANEOUS LEUPROLIDE ACETATE FORMULATIONS LASTING 1-6 MONTHS ACHIEVE AND MAINTAIN SERUM TESTOSTERONE LEVELS BELOW 20NG/DL IN 4 OPEN LABEL, FIXED DOSE STUDIES

The Journal of urology, 2015, Vol.193 (4), p.e936-e936

2015

Volltextzugriff (PDF)

Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne

Journal of the American Academy of Dermatology, 2004-11, Vol.51 (5), p.709-717

2004

Volltextzugriff (PDF)

Polymer-delivered, subcutaneously administered leuprolide acetate provides consistent and prolonged drug delivery in castrate men with advanced prostate cancer

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.e586-e586

2017

Volltextzugriff (PDF)

Polymer delivered, subcutaneously administered leuprolide acetate provides stable and long-term drug delivery and testosterone suppression in 4 pivotal trials

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.e592-e592

2017

Volltextzugriff (PDF)

Late administration of luteinizing hormone-releasing hormone (LHRH) agonists and the impact on testosterone suppression in the real-world management of prostate cancer

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.149-149

2019

Volltextzugriff (PDF)

Low incidence of microsurges with biodegradable polymer-delivered, subcutaneously-administered leuprolide acetate in prostate cancer patients

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.158-158

2019

Volltextzugriff (PDF)

Nadir testosterone (T) following in-situ polymer delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.204-204

2018

Volltextzugriff (PDF)

Onset and maintenance of testosterone suppression in four pivotal trials of subcutaneously administered leuprolide acetate formulated with in-situ forming polymeric delivery technology

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.205-205

2018

Volltextzugriff (PDF)

Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.172-172

2018

Volltextzugriff (PDF)

MP57-17 POLYMER DELIVERED, SUBCUTANEOUSLY ADMINISTERED LEUPROLIDE ACETATE PROVIDES STABLE AND LONG-TERM DRUG DELIVERY AND TESTOSTERONE SUPPRESSION ACROSS 4 PIVOTAL TRIALS

The Journal of urology, 2017-04, Vol.197 (4), p.e770-e770

2017

Volltextzugriff (PDF)

Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients

Journal of clinical oncology, 2017-02, Vol.35 (6_suppl), p.e589-e589

2017

Volltextzugriff (PDF)

BPI19-009: Late Administration of Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Testosterone Levels >50NG/DL in Prostate Cancer

Journal of the National Comprehensive Cancer Network, 2019-03, Vol.17 (3.5), p.BPI19-009

2019

Volltextzugriff (PDF)

Metabolism of 1α, 25-dihydroxyvitamin D3 and its C-3 epimer 1α, 25-dihydroxy-3-epi-vitamin D3 in neonatal human keratinocytes

Steroids, 2001-05, Vol.66 (3-5), p.441-450

2001

Volltextzugriff (PDF)

Continuous release, solid depot, subcutaneous leuprolide acetate formulations to achieve and maintain castrate level serum testosterone levels below 20ng/dL in 4 open label, fixed dose studies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16062-e16062

2015

Volltextzugriff (PDF)

MP73-16 SOLID DEPOT, CONTINUOUS RELEASE, SUBCUTANEOUS LEUPROLIDE ACETATE FORMULATIONS LASTING 1-6 MONTHS ACHIEVE AND MAINTAIN SERUM TESTOSTERONE LEVELS BELOW 20NG/DL IN 4 OPEN LABEL, FIXED DOSE STUDIES

The Journal of urology, 2015-04, Vol.193 (4), p.e936-e936

2015

Volltextzugriff (PDF)

Paradise locked : the 1918 influenza pandemic in American Samoa

Sites (Palmerston North, N.Z.), 2013-12, Vol.10 (2), p.30-51

McLane, John Ryan

2013

Volltextzugriff (PDF)

Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e16048-e16048

2015

Volltextzugriff (PDF)

Princeton Legacy Library

John R. McLane

2015

Volltextzugriff (PDF)

Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: A randomized trial

Journal of the American Academy of Dermatology, 2000-11, Vol.43 (5), p.777-784

2000

Volltextzugriff (PDF)

Metabolism of 1α,25-dihydroxyvitamin D 3 and its C-3 epimer 1α,25-dihydroxy-3-epi-vitamin D 3 in neonatal human keratinocytes

Steroids, 2001-03, Vol.66 (3), p.441-450

2001

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic comparison of subcutaneous intramuscular leuprolide acetate formulations in male subjects

Therapeutic advances in urology, 2018-02, Vol.10

2018

Volltextzugriff (PDF)

1 – 25 von 285

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(230)
Mit Volltextzugriff
(261)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(285)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer

Indian Nationalism and the Early Congress

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects

Analysis of common side effects of isotretinoin

MP73-16 SOLID DEPOT, CONTINUOUS RELEASE, SUBCUTANEOUS LEUPROLIDE ACETATE FORMULATIONS LASTING 1-6 MONTHS ACHIEVE AND MAINTAIN SERUM TESTOSTERONE LEVELS BELOW 20NG/DL IN 4 OPEN LABEL, FIXED DOSE STUDIES

Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne

Polymer-delivered, subcutaneously administered leuprolide acetate provides consistent and prolonged drug delivery in castrate men with advanced prostate cancer

Polymer delivered, subcutaneously administered leuprolide acetate provides stable and long-term drug delivery and testosterone suppression in 4 pivotal trials

Late administration of luteinizing hormone-releasing hormone (LHRH) agonists and the impact on testosterone suppression in the real-world management of prostate cancer

Low incidence of microsurges with biodegradable polymer-delivered, subcutaneously-administered leuprolide acetate in prostate cancer patients

Nadir testosterone (T) following in-situ polymer delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa)

Onset and maintenance of testosterone suppression in four pivotal trials of subcutaneously administered leuprolide acetate formulated with in-situ forming polymeric delivery technology

Testosterone (T) suppression by weight and age groups in four pivotal trials of in-situ forming polymer-delivered, subcutaneously administered leuprolide acetate in men with prostate cancer (PCa)

MP57-17 POLYMER DELIVERED, SUBCUTANEOUSLY ADMINISTERED LEUPROLIDE ACETATE PROVIDES STABLE AND LONG-TERM DRUG DELIVERY AND TESTOSTERONE SUPPRESSION ACROSS 4 PIVOTAL TRIALS

Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients

BPI19-009: Late Administration of Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Testosterone Levels >50NG/DL in Prostate Cancer

Metabolism of 1α, 25-dihydroxyvitamin D3 and its C-3 epimer 1α, 25-dihydroxy-3-epi-vitamin D3 in neonatal human keratinocytes

Continuous release, solid depot, subcutaneous leuprolide acetate formulations to achieve and maintain castrate level serum testosterone levels below 20ng/dL in 4 open label, fixed dose studies

MP73-16 SOLID DEPOT, CONTINUOUS RELEASE, SUBCUTANEOUS LEUPROLIDE ACETATE FORMULATIONS LASTING 1-6 MONTHS ACHIEVE AND MAINTAIN SERUM TESTOSTERONE LEVELS BELOW 20NG/DL IN 4 OPEN LABEL, FIXED DOSE STUDIES

Paradise locked : the 1918 influenza pandemic in American Samoa

Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere

Princeton Legacy Library

Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris: A randomized trial

Metabolism of 1α,25-dihydroxyvitamin D 3 and its C-3 epimer 1α,25-dihydroxy-3-epi-vitamin D 3 in neonatal human keratinocytes

Pharmacokinetic and pharmacodynamic comparison of subcutaneous intramuscular leuprolide acetate formulations in male subjects

Suchergebnisse filtern